Spyre Therapeutics, Inc. SYRE EV / sales
EV / sales at other companies
Other financials
Where this comes from
Calculated from Spyre Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed August 7, 2024, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s ev / sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s EV / sales?
- Spyre Therapeutics, Inc. (SYRE) reported EV / sales of -154.1× in Q2 2023.
- How has Spyre Therapeutics, Inc.'s EV / sales changed year-over-year?
- Spyre Therapeutics, Inc.'s EV / sales decreased by 7364.4% year-over-year, from 2.1× to -154.1×.
- What does EV / sales mean?
- What the whole business costs relative to its annual sales.
- How do you interpret EV / sales?
- A fallback valuation gauge for pre-profit or cyclical firms. Like P/S, only comparable across similar-margin businesses, but it accounts for debt and cash unlike P/S.
- How does EV / sales compare across companies?
- Compare within a margin cohort; the debt-and-cash adjustment makes it cleaner than P/S for leveraged firms.